|
|
Volumn 7, Issue 7, 2007, Pages 977-979
|
|
Medical management of advanced prostate cancer: A multidisciplinary team approach
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR;
AMINOGLUTETHIMIDE;
ATRASENTAN;
BEVACIZUMAB;
BORTEZOMIB;
CALCITRIOL;
DIETHYLSTILBESTROL;
DOCETAXEL;
ESTRAMUSTINE;
FLUTAMIDE;
GEFITINIB;
GONADORELIN DERIVATIVE;
GOSERELIN;
IMATINIB;
IXABEPILONE;
KETOCONAZOLE;
LAROTAXEL;
MEGESTROL;
MITOXANTRONE;
OBLIMERSEN;
PACLITAXEL;
PERTUZUMAB;
PROSTATE SPECIFIC ANTIGEN;
RADIOISOTOPE;
SATRAPLATIN;
SORAFENIB;
TAXANE DERIVATIVE;
TESTOSTERONE;
UNCLASSIFIED DRUG;
XRP 6258;
ADVANCED CANCER;
CANCER ADJUVANT THERAPY;
CANCER HORMONE THERAPY;
CANCER RESEARCH;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONFERENCE PAPER;
DIAGNOSTIC VALUE;
DRUG EFFICACY;
DRUG RESPONSE;
EVIDENCE BASED MEDICINE;
HIGH RISK PATIENT;
HUMAN;
INTERDISCIPLINARY COMMUNICATION;
MALE;
MEDICAL DECISION MAKING;
MEDICAL EDUCATION;
MEDICAL SPECIALIST;
PRACTICE GUIDELINE;
PREDICTION;
PROGNOSIS;
PROSTATE CANCER;
PROSTATECTOMY;
QUALITY OF LIFE;
TEAMWORK;
TESTOSTERONE BLOOD LEVEL;
TREATMENT OUTCOME;
UNSPECIFIED SIDE EFFECT;
ANTINEOPLASTIC AGENTS;
BRACHYTHERAPY;
CLINICAL TRIALS;
COMBINED MODALITY THERAPY;
HUMANS;
MALE;
PATIENT CARE TEAM;
PROSTATE-SPECIFIC ANTIGEN;
PROSTATIC NEOPLASMS;
|
|
EID: 34547499709
PISSN: 14737140
EISSN: 17448328
Source Type: Journal
DOI: 10.1586/14737140.7.7.977 Document Type: Conference Paper |
|
Times cited : (4)
|
|
References (0)
|
